However, there is another problem; the concentration of the Grp94/peptide sarcoma vaccine that was used was not necessarily the optimal concentration to stimulate an effective immune response because of the problem of quantifying the Grp94/peptide. This evidence concerns the gene HSP90B1 and sarcoma.